April 2023 Content Release Copied
Clinical Profile Documentation
AJCC 8th Edition Staging
This release contains updates to align with the Cotswold modification of the Ann Arbor system to the Lugano Classification system for the following problem groups:
- Lymphoma, Non-Hodgkins (NHL), Other
The staging row will display updated Stage values based on the changes. The new content does not affect previous charting documented on existing patients. All previous charting is brought forward during a subsequent visit, just as it did prior to this release.
The following documentation points are now available:
- I
- IE
- II
- IIE
- II bulky*
- III
- IV
- Unknown
AJCC 9th Version Staging
This release contains updated TNM values, Staging Groups, and Template functionality to align with AJCC version 9 conditions for:
- Malignant, Thymoma
Users will see updated values and descriptions for Primary Tumor Type (T), Regional Lymph Nodes (N), and Distance Metastasis (M), documentation points.
The staging calculator will display updated Stage values based on the changes to the staging groups. The new content does not affect previous charting documented on existing patients. A summary table is provided below.
All previous charting is brought forward during a subsequent visit, just as it did prior to this release.
Lab Analytes & Panels
Additions
- Alder (T2), IgE
- Allergen Region 17 respiratory IgE panel
- Alternaria alternata (M6), IgE
- Amph/Methamphtetamines, urine, qual
- Anaerobic and Aerobic wound culture and gram stain
- APTT mixing study panel
- Ash, white (T15), IgE
- Aspergillus fumigatus (M3), IgE
- ATP1B1
- Birch tree, IgE
- BK virus DNA, quant PCR, plasma, IU/mL
- Cat epithelium/dander (E1), IgE
- CBC w/Auto Diff/ IPF w/ Reflex
- CBC w/Auto Diff/ IPF w/OUT Reflex
- Cedar, mountain (T6), IgE
- Coag consult level limited
- Cockroach, German, IgE
- Cottonwood tree (T14), IgE
- farinae mite (D2), IgE
- pteronyssinus (D1), IgE
- Dog dander (E5), IgE
- Elm tree, IgE
- Hormodendrum hordei, IgE
- Immunoglobulin E
- Lymphocyte subset panel 4 information
- Maple/Box elder (T1), IgE
- Mouse epithelium, IgE
- Mucor racemosus (M6), IgE
- Nettle (W20), IgE
Medications
Additions
- Azeliragon invest Oral
- Iberdomide invest Oral
- Isatuximab invest Subcutaneous (via wearable injector)
- Narazaciclib invest (ON 123300 invest Oral)
- Semaglutide-Cyanocobalamin Subcutaneous
- Oak tree (T7), IgE
- notatum, IgE
- Pigweed, IgE
- POC INR
- POC protime
- PTT 1Hr 1:1 mix, sec
- PTT 1Hr undiluted, sec
- PTT immed 1:1 Mix, sec
- PTT immed undil, sec
- PTT mix study interpretation
- Ragweed, short/common (W1), IgE
- Reticulocyte count method
- RPR monitoring
- RPR monitoring panel
- Sheep sorrel (W18), IgE
- Stool culture micro number
- Stool culture source
- Stool culture specimen quality
- Stool culture status
- Syphilis Ab, IGG IGM serum, qual
- Timothy grass (G6), IgE
- Varicella zoster virus DNA, RT-PCR, quant
- Venous thrombosis evaluation consultation level
- Venous thrombosis evaluation interpretation
- Walnut tree (T10), IgE
- Weekend CBC w/Auto Diff w/ Reflex
- Weekend CBC w/Auto Diff w/OUT Reflex
Updates
| Medication | Update |
| Bendamustine IV | New Quick Sigs:
|
| Bendamustine invest IV | Excluded from end-user search |
| Desmopressin IV | New max single dose: 20 mcg
New quick sigs:
New instructions: For Hemophilia A and Von Willebrand’s Disease: If used preoperatively, administer 30 minutes prior to procedure. If used to reduce spontaneous or traumatic bleeding, doses may be repeated after 8 to 12 hrs. and once daily thereafter, if needed, based on clinical condition of the patient and laboratory response. |
| Etoposide IV | Removed instructions:
New sigs:
|
| Sacituzumab Govitecan-hziy IV | New max single dose: 1500 mg
New instructions: Dilute in NS to a final concentration of 1.1 to 3.4 mg/mL in a PVC, PP/PE, PO, or EVA infusion bag. Do not freeze. Do not shake. Protect from light. First infusion: Administer over 3 hours. Subsequent infusions: Administer over 1 to 2 hours if prior infusions were tolerated. Do not administer IV push or bolus. Do not mix or infuse with other drugs. Observe patient for signs or symptoms of infusion-related reactions during each infusion and for at least 30 minutes after each infusion. Flush with 20 mL NS following infusion. |
Regimen Library
Additions
| Regimen Name | Diagnosis |
| Bendamustine D1,2 Q28D (Waldenstroms) | Waldenstrom’s Macroglobulinemia |
| Cisplatin D1,22 + XRT Q42D fb Paclitaxel + Carboplatin Q21D (Part 1 of 2) | Uterine Cancer (Parent) |
| Cisplatin D1,22 + XRT Q42D fb Paclitaxel + Carboplatin Q21D (Part 2 of 2) | Uterine Cancer (Parent) |
| Darbepoetin alfa Q7D (Myelofibrosis) Supportive Care | Myelofibrosis |
| Enfortumab vedotin-ejfv D1,8 + Pembrolizumab Q21D | Bladder Cancer, Renal Pelvis and Ureter Cancer, Urethral Cancer |
| Epoetin alfa Q7D (Myelofibrosis) Supportive Care | Myelofibrosis |
| Fludarabine D1-3 + Cyclophosphamide D1-3 + Rituximab IV (FCR) Q28D (Waldenstroms) | Waldenstrom’s Macroglobulinemia |
| Fludarabine D1-5 + Rituximab IV Q28D | Waldenstrom’s Macroglobulinemia |
| Lusutrombopag | All Problems |
| Retifanlimab-dlwr Q28D | Merkel Cell Carcinoma |
| Rituximab IV + Ixazomib D1,8,15 + Dexamethasone Q28D fb Q56D | Waldenstrom’s Macroglobulinemia |
| Rituximab IV D2 + Carfilzomib D1,2 + Dexamethasone Q56D (Part 2 of 2: Maintenance) | Waldenstrom’s Macroglobulinemia |
| Rituximab IV D2,9 + Carfilzomib D1,2,8,9 + Dexamethasone Q21D (Part 1 of 2: Induction) | Waldenstrom’s Macroglobulinemia |
| Rituximab IV D1,8,15,22 Q84D | Waldenstrom’s Macroglobulinemia |
| Rituximab IV + Cladribine SQ D1-5 Q28D (Waldenstroms) | Waldenstrom’s Macroglobulinemia |
| Rituximab IV + Cyclophosphamide PO D1-5 + Dexamethasone Q21D | Waldenstrom’s Macroglobulinemia |
| Rituximab IV + Cyclophosphamide + Prednisone Q21D | Waldenstrom’s Macroglobulinemia |
| Venetoclax Q30D (Waldenstroms) | Waldenstrom’s Macroglobulinemia |
Updates
Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.
- Anal Cancer (Parent)
- Bladder Cancer
- Breast Cancer
- Cancer of Unknown Primary
- Cervical Cancer
- Esophageal Cancer (Parent)
- Fallopian Tube Cancer
- Gastric Cancer
- Head and Neck Cancer (Parent)
- Kaposi’s Sarcoma
- Lung Cancer, Non-small Cell (NSCLC)
- Lung Cancer, Small Cell (SCLC)
- Melanoma, Skin
- Ovarian and Primary Peritoneal Cancer
- Renal Pelvis and Ureter Cancer
- Testicular Cancer (Parent)
- Urethral Cancer
- Uterine Cancer (Parent)
Research
Updates
| Updated Reference Information | Updated Drug Service Order Information | Updated Regimen Instructions | Other Change | |
| USOR 20208 | X | X | ||
| USOR 21173 | X | |||
| USOR 21228 | X | X | X | |
| USOR 21326 | X | X | USOR 21356 | X | X | Now available:
USOR 21356 Optional Maintenance Mosunetuzumab SC Q56D |
| USOR 21498 | X | X | X | |
| USOR 21527 | X | X | X | |
| USOR 21546 | X | |||
| USOR 22003 | X | |||
| USOR 22042 | X | X | ||
| USOR 22049 | X | X | X | |
| USOR 22107 | X | X | X |
Billing & HCPCS Codes
Updates
| Medication | HCPCS Codes |
| Acetaminophen IV | J3490 per 1000 mg |
| Bevacizumab-adcd IV (Vegzelma) | Q5129 per 10 mg |
| Carmustine IV | J3490 per 100 mg |
| Furosemide | J3490 per 20 mg |
| Glycopyrrolate | J3490 per 0.2 mg |
| Retifanlimab-dlwr IV (Zynyz) | J3590 per 500 mg |
| Varicella Virus Vaccine Live (PF) (Varivax) | 90749 per 0.5 mL |
| Vilobelimab IV (EUA) (Gohibic) | J3590 per 200 mg |
NDC & HCPCS Crosswalk
Updates
| Medication | HCPCS Code | NDC |
| Acetaminophen IV | J3490 per 1000 mg | 00143938601 00143938610 |
| Carmustine, IV | J3490 per 100 mg | 16729054305 16729054563 16729054601 16729054863 |
| Furosemide | J3490 per 20 mg | 81565020102 81565020101 |
| Camcevi (Leuprolide Subcutaneous (6 month) | J1952 per 1 mg | 169448001463 |